A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the baylor experience)

This publication has 15 references indexed in Scilit:

• Salvage treatment for recurrent squamous cell carcinoma of the oral cavity
  Head & Neck, 2000
• Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group.
  Journal of Clinical Oncology, 1998
• p53 Expression: Predicting Recurrence and Second Primary Tumors in Head and Neck Squamous Cell Carcinoma
  JNCI Journal of the National Cancer Institute, 1996
• Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck
  Annals of Oncology, 1994
• Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.
  Genes & Development, 1993
• Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
  Journal of Clinical Oncology, 1992
• Prognostic Factors in the Recurrence of Stage I and II Squamous Cell Cancer of the Oral Cavity
  JAMA Otolaryngology–Head & Neck Surgery, 1992
• A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck
  British Journal of Cancer, 1990
• Treatment Outcome in Recurrent Head and Neck Cancer
  Archives of Surgery, 1979
• Carcinoma of the floor of mouth: an analysis of treatment results and the sites and causes of failures
  International Journal of Radiation Oncology*Biology*Physics, 1976